NCT06159621View on ClinicalTrials.gov

CD40 Agonist and PD-1 Inhibitor in HNSCC

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2028

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

PD-1inhibitor - LVGN 3616

Administration of one dose of LVGN 3616 - 300mg. Commercially available PD-1 inhibitor may be substituted.

DRUG

CD 40 Agonist - LVGN 7409

Administration of one dose of LVGN 7409 - 1mg/kg

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT06159621 - CD40 Agonist and PD-1 Inhibitor in HNSCC | Biotech Hunter | Biotech Hunter